Dyne Therapeutics Stock Rises on Positive DM1 Trial Results

3-line summary

• Dyne Therapeutics shares rose on positive DM1 (myotonic dystrophy type 1) trial results, according to an Investing.com report.

This summary is our own processing of the source article; see the source link below for full context.